UK Trade & Investment is the Government Department that helps UK-based companies succeed in the global economy. We also help overseas companies bring their high-quality investment to the UK’s dynamic economy acknowledged as Europe’s best place from which to succeed in global business.

UK Trade & Investment offers expertise and contacts through its extensive network of specialists in the UK, and in British embassies and other diplomatic offices around the world. We provide companies with the tools they require to be competitive on the world stage.

Part of the UK Government’s portfolio of Solutions for Business

To find out more, scan this code with your smart phone. www.ukti.gov.uk +44(0)20 7215 5000

Published in November 2013 by UK Trade & Investment © Crown Copyright

www.ukti.gov.uk/lifesciences

Whereas every effort has been made to ensure that the information given in this

document is accurate, neither UK Trade & Investment nor its parent Departments (the Department for Business, Innovation and Skills, and the Foreign & Commonwealth

Office) accept liability for any errors, omissions or misleading statements, and no warranty is given or responsibility accepted

as to the standing of any individual, firm, company or other organisation mentioned.

INNOVATION IS

Unlock Your Global Business PotentialMedical ImagingUKTI Life Science Investment Organisation (LSIO)

Market SuccessJoin other international and UK businesses in exploiting the expertise and opportunities that can help your business develop and launch its technology into the marketplace.

Lightpoint Medical receives award from Technology Strategy Board to develop hand-held imaging technologyLightpoint Medical is an early-stage medical device company dedicated to improving health outcomes for cancer patients through image-guided surgery. The company’s hand-held molecular imaging technology, based on Cerenkov luminescence imaging, has the potential to detect cancer in real-time during surgery, thereby providing more accurate cancer treatment while sparing healthy tissue. The technology’s 100-fold lower cost and size relative to a PET scanner make it a potentially disruptive technology.

Nearly 1 in 4 patients who undergo surgery for early-stage breast cancer will require repeat operation. We aim to address this enormous medical need through our proprietary molecular imaging technology. This award builds on our successful private fundraising and previous Technology Strategy Board grants.” Dr David Tuch, CEO of Lightpoint Medical

University of Leeds Medical Technologies Innovation and Knowledge Centre forge R&D partnership with Siemens Healthcare Senior researchers at Leeds Musculoskeletal Biomedical Research Unit (LMBRU) are working with Siemens Healthcare to maximise the potential of an advanced MRI imaging technology. The team is working with the new technology to refine new product development applications and to improve support for clinical trials and therapeutic decision making for orthopaedic medical devices. This latest MRI technology is providing an earlier and clearer understanding of implant performance, principally by delivering surrogate outcome measures for fixation failures. These measures are expected to be especially valuable in studies related to implanted devices where pathology in peri-implant soft tissue is either unseen or distorted in images derived using conventional current MRI technologies.

Unlock Your Global Business Potential: Medical Imaging

Market OpportunityMedical Imaging has the potential to address many of the challenges facing healthcare.

Today’s system is high cost, with treatment being deployed too late.

By 2025 healthcare spend and technology innovation will

increasingly focus on predicting, diagnosing and monitoring. The prime driver for this shift will be centred around catching the disease earlier in some cases before symptoms are present in order to improve health outcomes and reduce the downstream costs of care.

As modern medicine moves towards stratifying treatment

(right drug, right patient at the right time), imaging technologies will have a key role in supporting the pharmaceutical industry at every stage of the drug development pathway, from lead to candidate through to launch and lifecycle management.

The UK market for diagnostic imaging in healthcare is

estimated at £1,133mn (US$1,836mn) in 2013, equal to 18.6% of the total medical device market and is forecast to reach a total value of £1,709mn (US$2,769mn) by 2018.The three largest routes to the healthcare market in the UK are:

1. The UK National Health Service (NHS) which in 2011-12 spent approximately £128bn (US$207bn) across the UK. Within England some Specialised Services (such as Proton Beam Therapy) are centrally commissioned with the majority of the remaining services/technologies being procured by regional NHS organisations.

2. The UK private healthcare market is growing and is estimated to reach £35bn (US$57bn) by 2015.

3. The UK social care market, dominated by assistive technologies, is set to grow from £2bn (US$3.3bn) in 2012 to £6bn (US$9.7bn) in 2020.

UKTI Life Science Investment Organisation (LSIO)UKTI has established a dedicated unit, the Life Science Investment Organisation (LSIO), to act as your interface with the UK life science sector.

The LSIO is your guide to identifying research, development and delivery partners and will support you through every step of investing in and working in the UK. The UKTI LSIO team will work closely with you to understand your needs and requirements, partnering you with the right people in the UK.

For further information please contact the UKTI LSIO team at:

World-class resources, talent and facilities provide a range of opportunities for your business to collaborate and innovate

• The UK’s excellence in medical imaging continues to flourish. Ranked first for relative world impact in the neuroimaging field and third for radiology, nuclear medicine, medical imaging, imaging science and photographic technology1.

• Cancer Research UK and the Engineering and Physical Sciences Research Council (EPSRC) are together committing funding of £35mn for four cancer imaging centres to develop new imaging techniques and applications, to help learn more about tumours, how cancer cells signal to one another, and molecular and genetic signatures.

• Five Academic Health Science Centres lead university, NHS and industry collaboration in imaging research offering the ability to translate findings from basic research into excellent translational, clinical and applied research across a variety of imaging modalities, software, tracers and contrast media.

Opening up data to drive research, clinical translation through to outcomes analysis

• UK Biobank is a major national health resource of 500,000 volunteers with biosamples, clinical records, and patient histories.

• Clinical Practice Research Datalink provides an observational data and interventional research service using extensively linked clinical information from GPs, hospitals, audit datasets, disease registries.

• The Health and Social Care Information Centre collects data from across the health and social care system and provides a range of information services and products to support the commissioning, design and delivery of health and care services.

A national clinical research infrastructure enabling efficient trial design and delivery

• A £500 million annual investment in the National Institute for Health Research (NIHR) infrastructure enables you access to:— Imaging focused Biomedical Research Centres

providing a direct route to work with the UK’s leading investigators and clinicians with the expertise to translate fundamental biomedical research into new and improved approaches to healthcare.

— Support through the NIHR Clinical Research Network (CRN) providing direct access to the infrastructure.

— NIHR Translational Research Partnerships which bring together:

— Expertise in pathophysiology and disease mechanisms, expertise in modelling.

— Enabling technologies and infrastructure, including imaging, biobanks, accredited laboratory facilities.

— Cohorts of well-characterised patients available for clinical development studies.

Home to robust regulators, health economists and a gateway to Europe & global markets

s

• The Medicines and Healthcare products Regulatory Agency and European Medicines Agency are both globally-respected UK and EU regulators respectively.

• The National Institute for Health and Care Excellence (NICE) provides world class health technology assessment.

• Academic Health Science Networks facilitate adoption and dissemination of innovative technologies into the NHS..

• UK Trade & Investment enables you to grow your business and to expand from the UK into new markets.

E: enquiries@ukti-invest.com www.ukti.gov.uk/lifesciences

@UKTI_LSIOT: +44 (0)20 7333 5442

Ease of Doing BusinessGovernment continues to improve the UK’s business environment, offering businesses:

• Low corporation tax rate, dropping to 21% by April 2014 and 20% in 2015.

• Patent Box reducing corporation tax on profits from UK patents to 10%.

• R&D tax relief for both large corporations and small and medium-sized enterprises (SMEs) investing in R&D in the UK – applicable to direct research costs as well as contract research costs.

• Regional Growth Fund (RGF) a £3.2 billion fund, helping companies throughout England to create jobs between now and the mid-2020s.

• £180 million Biomedical Catalyst non-dilutive funding for translation and commercialisation.

• The NIHR Invention for Innovation (i4i) supports R&D collaborations and projects through prototype and commercial development to introduction and adoption into the NHS.

• The Technology Strategy Board Smart Scheme:

— offers funding to SMEs to engage in R&D projects.

— aims to invest up to £4.5mn in collaborative R&D to improve cell and tissue analysis for stratified medicine for collaborative R&D funding.

The use of ultrasound equipment in medicine has transformed diagnosis and the observation of prenatal development.

The invention of a commercially viable CAT scanner in the UK opened the door to a new branch of imaging which has become a mainstay of diagnostic imaging.

The discovery of the potential of nuclear magnetic resonance to visualise internal structures has transformed diagnostic imaging.

A research group at Edinburgh University developed a technique called tissue ‘Doppler’ imaging, which has improved ultrasound images.

The innovations in robotics and the medical adoption of robotics for minimally invasive imaging during surgery are providing on-going quality benefits to patients.

Rich Diverse Ecosystem

1. Web of Science, Thomson Reuters (2011)

The UK has a rich heritage of innovation and discovery across a variety of imaging modalities

£1,133mn 2013 £1,709mn 2018